Pathogen proteotyping: A rapidly developing application of mass spectrometry to address clinical concerns
Clinical Mass Spectrometry · 2019-09 · 14 · 9-17
DOI: 10.1016/j.clinms.2019.04.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Mass Spectrometry, 2019-09. Verfasst von Lucia Grenga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI), CEA, INRA, F-30207…. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Commissariat à l'Énergie Atomique et aux Énergies Alternatives.
Abstract (Originalsprache)
For the rapid and reliable differentiation of clinically-relevant bacterial species, mass spectrometry-based methods have emerged in recent years as valid alternatives to existing techniques. Mass profiles generated by whole-cell Matrix-Assisted Laser Desorption Ionization-Time of Flight mass spectrometry have revolutionized microorganism identification and proven their potential for proteotyping at the species level. Indeed, the methodology has been widely deployed in clinical settings. However, the low resolution and dynamic range of the methodology has limited its capacity to distinguish between subspecies. This discrimination capacity is pivotal in cases where certain strains display virulence or antibiotic resistance, and for epidemiologic analyses. Moreover, sensitivity and specificity are both key parameters when attempting to discriminate between microorganisms present in complex multi-pathogenic samples. These two parameters are also essential to meet the growing interest in the characterization of microorganisms contained within even more complex samples, such as the human microbiome. Tandem mass spectrometry, with its high resolution, holds great potential for use in the real-time direct analysis of pathogens at the most relevant taxonomic rank in routine clinical practice. This review explores the numerous benefits and challenges of implementing advanced proteotyping methods, based on tandem mass spectrometry, in clinical laboratories. We provide an overview of the current applications and methodologies, while also discussing recent improvements and potential new approaches for typing, as well as their future applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI), CEA, INRA, F-30207 Bagnols sur Cèze, France.
Förderung
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives
Zitieren
APA
Grenga, L., Pible, O., & Armengaud, J. (2019). Pathogen proteotyping: A rapidly developing application of mass spectrometry to address clinical concerns. Clinical Mass Spectrometry, 14, 9-17. https://doi.org/10.1016/j.clinms.2019.04.004
Vancouver
Grenga L, Pible O, Armengaud J. Pathogen proteotyping: A rapidly developing application of mass spectrometry to address clinical concerns. Clinical Mass Spectrometry. 2019;14:9-17. doi:10.1016/j.clinms.2019.04.004
BibTeX
@article{Grenga2019,
author = {Grenga, Lucia and Pible, Olivier and Armengaud, Jean},
title = {Pathogen proteotyping: A rapidly developing application of mass spectrometry to address clinical concerns},
journal = {Clinical Mass Spectrometry},
year = {2019},
volume = {14},
pages = {9--17},
doi = {10.1016/j.clinms.2019.04.004}
}
EUVIMED